meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus pemetrexed and platin
pembrolizumab based treatment
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab based treatment
pembrolizumab and pemetrexed plus platin
non squamous - mNSCLC - L1 - Wild Type (WT)
6
Comparator:
vs pemetrexed plus platin;
Risk of bias:
low;
some concerns;
high;
NA;